Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab/Tiragolumab - Roche

Drug Profile

Atezolizumab/Tiragolumab - Roche

Alternative Names: Atezolizumab/Tiragolumab; MPDL 3280A/MTIG 7192A; RG 7446/RG 6058; RG7446 42/RG6058 11; RO 5541267/RO 7092284

Latest Information Update: 03 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 22 Dec 2022 Preclinical trials in Solid tumours in Switzerland (IV) (NCT05661578)
  • 22 Dec 2022 Roche plans phase II SKYSCRAPER-11 trial (Late-stage disease, Recurrent and Metastatic disease) in Solid tumours (IV) (NCT05661578) (EudraCT Number-2022-001157-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top